EverFortune.AI Co., Ltd. announced on 30 May the signing of a Memorandum of Understanding with the Queen Elizabeth II Hospital in Malaysia, the company will provide seven artificial intelligence software services related to cardiovascular and thoracic surgery at Queen Elizabeth II Hospital, which will significantly accelerate the hospital's diagnostic process. 

It is one of the leading hospitals in Sabah and is the centre for cardiac and thoracic surgery in Sabah. Its Clinical Research Centre is also one of the 37 clinical research centres under the Malaysian Institute of Health.

The collaboration with EverFortune.AI focuses on seven FDA and TFDA cleared cardiac and thoracic related products, including ECG analysis software, acute myocardial infarction detection software, myocardial perfusion image analysis and reporting system, cardiothoracic ratio estimation system, pneumothorax detection system, cribriform effusion detection system, and image recording and transmission system. 

The introduction of the seven AI medical softwares is expected to significantly speed up the hospital's diagnostic process, reduce patient waiting times, increase the hospital's diagnostic capacity, provide a broader range of medical services, enable physicians to quickly review patient images and reduce the risk of missed interpretations, allow physicians to focus on abnormal image interpretation and analysis, and reduce the time spent on normal image analysis and report writing. 

With a wide range of products in the cardiovascular field, EverFortune.AI is no less than the top tier medical AI companies in Europe and the US, and with more affordable products and a more ergonomic user interface, it will enable Elizabeth II Hospital to significantly improve its smart healthcare in the shortest possible time.

It is the first company in Taiwan to be listed on the Taiwan Stock Exchange to specialise in medical AI for acute medical conditions such as "neurology", "cardiovascular" and "cancer", and has received 10 TFDA and 6 FDA approvals for medical devices in Taiwan and has customers in over 40 medical institutions and enterprises worldwide, including the US, France, Singapore, Hong Kong, China and Taiwan.